Redeye: Episurf Medical Q3 - Slashing cost
Redeye provides a more in-depth review of Episurf Medical’s Q3 report. On the back of announcements made during the quarter, we have made some downward adjustments to our sales estimates and now factor in a capital injection in H2 2025e. Our financial estimates revision and the inclusion of a capital injection renders a drastically lower fair value range.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/